18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy

Eric C. Ford; Joseph Herman; Ellen Yorke; Richard L. Wahl

doi:10.2967/jnumed.108.055780

¹⁸F-FDG PET/CT for image-guided and intensity-modulated radiotherapy

Eric C. Ford, Joseph Herman, Ellen Yorke, Richard L. Wahl

Research output: Contribution to journal › Review article › peer-review

112 Scopus citations

Abstract

Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. ¹⁸F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of ¹⁸F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of ¹⁸F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.

Original language	English (US)
Pages (from-to)	1655-1665
Number of pages	11
Journal	Journal of Nuclear Medicine
Volume	50
Issue number	10
DOIs	https://doi.org/10.2967/jnumed.108.055780
State	Published - Oct 1 2009
Externally published	Yes

Keywords

FDG (fluorodeoxyglucose)
FDG PET/CT
IGRT
IMRT
Radiation therapy

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2967/jnumed.108.055780

Cite this

@article{753330cc34024a9085d378a80f411247,

title = "18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy",

abstract = "Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. 18F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of 18F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of 18F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.",

keywords = "FDG (fluorodeoxyglucose), FDG PET/CT, IGRT, IMRT, Radiation therapy",

author = "Ford, {Eric C.} and Joseph Herman and Ellen Yorke and Wahl, {Richard L.}",

year = "2009",

month = oct,

day = "1",

doi = "10.2967/jnumed.108.055780",

language = "English (US)",

volume = "50",

pages = "1655--1665",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "10",

}

TY - JOUR

T1 - 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy

AU - Ford, Eric C.

AU - Herman, Joseph

AU - Yorke, Ellen

AU - Wahl, Richard L.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. 18F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of 18F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of 18F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.

AB - Advances in technology have allowed extremely precise control of radiation dose delivery and localization within a patient. The ability to confidently delineate target tumor boundaries, however, has lagged behind. 18F-FDG PET/CT, with its ability to distinguish metabolically active disease from normal tissue, may provide a partial solution to this problem. Here we review the current applications of 18F-FDG PET/CT in a variety of disease sites, including non-small cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma. This review focuses on the use of 18F-FDG PET/CT to aid in planning radiotherapy and the associated benefits and challenges. We also briefly consider novel radiopharmaceuticals that are beginning to be used in the context of radiotherapy planning.

KW - FDG (fluorodeoxyglucose)

KW - FDG PET/CT

KW - IGRT

KW - IMRT

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=70349633882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349633882&partnerID=8YFLogxK

U2 - 10.2967/jnumed.108.055780

DO - 10.2967/jnumed.108.055780

M3 - Review article

C2 - 19759099

AN - SCOPUS:70349633882

SN - 0161-5505

VL - 50

SP - 1655

EP - 1665

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 10

ER -